



REVIEW ARTICLE

Microbial Infections and Antimicrobial Resistance in Nepal: Current Trends and Recommendations

Ram H. Dahal^{1,*} and Dhiraj K. Chaudhary²

¹Department of Microbiology, Tri-Chandra Multiple Campus, Tribhuvan University, Katmandu, Nepal

²Department of Soil Science, Prithu Technical College, Institute of Agriculture and Animal Science, Tribhuvan University, Lamahi, Dang, Nepal

Received: March 24, 2018

Revised: June 25, 2018

Accepted: July 03, 2018

Abstract: Antimicrobial resistance is a life threatening challenges to the world. Most of the well-known antibiotics are currently ineffective to several microbial diseases. Ampicillin, metronidazole, amoxicillin, cotrimoxazole, chloramphenicol, ciprofloxacin, nalidixic acid, gentamicin, and ceftazidime are common antibiotics whose resistance pattern has been elevated in recent years. The rise and dissemination of resistant bacteria has contributed in increasing cases of antimicrobial resistance. Multi-drug Resistant (MDR) organism such as *Staphylococcus aureus*, *Pseudomonas aeruginosa*, *Escherichia coli*, and *Mycobacterium tuberculosis* are principal problems for public health and stakeholders. Globally, issues of antimicrobial resistance are major concern. In the context of Nepal, insufficient surveillance system, lack of appropriate policy, and poor publications regarding the use of antibiotics and its resistance pattern has misled to depict exact scenario of antimicrobial resistance. This mini-review presents current trends of antibiotic use and its resistance pattern in Nepal. In addition, global progression of antibiotic discovery and its resistance has been covered as well. Furthermore, use of antibiotics and possible ways on improvement of effectiveness have been discussed.

Keywords: Antimicrobial resistance, Microbial infection, Antibiotic susceptibility, MRSA, MDR, Nepal.

1. INTRODUCTION

Antimicrobial agents also called antibiotics are the crucial drugs obtained from microorganisms to prevent and treat bacterial infections. The role of antibiotics came into action when Alexander Fleming discovered the penicillin in 1928 [1]. Most of the (about 75%) antibiotics that are currently in clinical use are obtained from actinobacteria isolated either from soil or water [2 - 4]. To date, continuous uses of antibiotics have created ineffectiveness to antibiotics, leading global rise in drug-resistant bacteria [5]. In recent years, several microbial infectious diseases are no longer responding to commonly used antimicrobial drugs which have elevated multi-drug resistance. The rise and spread of resistant bacteria is a major threat to public health and a unique challenge to both science and medicine [6]. Multi-drug Resistant (MDR) organisms (*Enterococcus* spp., *Klebsiella* spp., *Enterobacter* spp., *Staphylococcus aureus*, *Pseudomonas aeruginosa*, *Acinetobacter baumannii*, *Propionibacterium acnes*, *Staphylococcus epidermidis*, *Escherichia coli*, and *Mycobacterium tuberculosis*) are considered as clinical threat to human and animals [7 - 12]. The Center for Disease Control and Prevention (CDC) assessed antimicrobial-resistant microbial infections according to various aspects: clinical impact, economic impact, incidence, 10-year projection of incidence, transmissibility, availability of effective antibiotics, and barriers to prevention [13, 14].

Antimicrobial resistance occurs when pathogenic bacteria degrade antibacterial drugs, alter bacterial proteins, and modify membrane permeability to antibiotics [15]. Taking antibiotics without doctor's prescription as well as medicating antibiotics unnecessarily for treatment of normal viral illness such as common cold, is a good example for

* Address correspondence to this author at the Department of Microbiology, Tri-Chandra Multiple Campus, Tribhuvan University, GPO Box 5859, Sundhara, Kathmandu, Nepal; Tel: +977-9841-246887; E-mail: ramhari.dahal@gmail.com

increment of antimicrobial resistance [16, 17]. The CDC estimates that antibiotic resistance is responsible for more than two million infections and 23,000 deaths each year in the United States [18]. The therapeutic consumption of antibiotics is increasing continuously and the demands of antibiotics continue to rise exponentially. In a decade of 2000-2010, the total global antibiotic consumption was raised by 30% [19].

Similar as global issue, the antimicrobial-resistance is also a serious complication in Nepal. However, there are no sufficient surveillance system for tracking current antibiotic use and its resistant pattern in Nepal. In addition, few research and published literatures are not abundant to elucidate current scenario. It is truly difficult to report exact trends of antibiotic use and its resistance in Nepal. Therefore, this review accentuates the antibiotic discovery and resistance, the current trends of antibiotic use, its resistance, and extending antibiotic effectiveness in the context of Nepal.

2. ANTIMICROBIAL RESISTANCE OF VARIOUS MICROBIAL PATHOGENS

Various antimicrobial agents, effective previously, are no longer useful today because of rise of resistance genes in the microbial genome [20]. Resistance genes emerge through natural selection in the environment over long period of time or by spontaneous mutation in the microbial DNA [21]. Resistant pattern has been reported by almost all antibiotics that have been developed so far (Fig. 1). The infections caused by antimicrobial-resistant microorganisms often fail to respond to the standard treatment or drug therapy, which result prolonged illness and fatal risk [22].



Fig. (1). Descriptive timeline of discovery and resistance of antibiotics.

The main cause of premature mortality and morbidity in Nepal are from bacterial origin. Major infections include acute respiratory infections, diarrheal disease, tuberculosis, and bloodstream infections. For inpatient morbidity, out of 287,616 hospitalized patients in 2014-2015, 11,529 patients were hospitalized due to diarrhea and gastroenteritis followed by other chronic obstructive pulmonary disease (8,053) and unspecified acute lower respiratory infections (7,881), which were the leading cause for hospitalization [23]. Pneumonia, diarrhea, and sepsis are the major health risk for neonates and infants. However, under-five, the infant and neonatal mortality in Nepal have been decreased by 79.59% in the year 1990-2015 [24]. There were 502 new diarrheal cases per 1,000 children under five years in 2014-2015 and number of diarrheal death were 80 [24].

2.1. Enteric Pathogens

Enteric microbial pathogens are those that cause severe diarrhea and dysentery which include rotavirus, *Shigella* spp., *Vibrio cholerae*, *Salmonella* spp., enterotoxigenic *Escherichia coli* (ETEC), enteroaggregative *Escherichia coli* (EAEC) and *Campylobacter* spp [25]. In most of the diarrheal cases, antibiotics are not required for complete recovery except some complications like bloody diarrhea. However, antibiotics are often used to treat in most diarrheal cases inappropriately [26].

Vibrio cholerae is a causative agent for severe watery diarrhea, which can lead to dehydration and even death. It is usually caused due to contaminated water or food. In Nepal, cholera outbreak is still a serious issue. Nearly, all *Vibrio cholerae* isolates (clinical and environmental) were resistant to cotrimoxazole, nalidixic acid, furazolidone, erythromycin, and ampicillin [27 - 30]. In addition, resistant strains of *Vibrio cholerae* were also reported for antibiotics chloramphenicol and ciprofloxacin (Table 1).

Table 1. Antibiotic resistance in *Vibrio cholerae*.

Microorganism	Study Area	No. of Isolates	Antibiotics	Resistance (%)	Reference
<i>Vibrio cholerae</i> (Clinical isolate)	Kathmandu city	22	Ampicillin	100	[27]
			Nalidixic acid	100	
			Cotrimoxazole	100	
			Erythromycin	90.9	
			Cefotaxime	18.2	
			Chloramphenicol	9.1	
<i>Vibrio cholerae</i> (Environmental isolate)	Kathmandu city	2	Ampicillin	100	[27]
			Nalidixic acid	100	
			Cotrimoxazole	100	
			Erythromycin	100	
			Chloramphenicol	50	
<i>Vibrio cholerae</i>	National Public Health Laboratory, Kathmandu	31	Ampicillin	100	[28]
			Cotrimoxazole	100	
			Ciprofloxacin	6.45	
			Chloramphenicol	3.23	
<i>Vibrio cholerae</i>	National Public Health Laboratory, Kathmandu	57	Nalidixic acid	100	[30]
			Cotrimoxazole	100	
			Furazolidone	100	
			Erythromycin	32	
			Ampicillin	26	

In the study of *Salmonella* and *Shigella* spp., most of the species were reported to have multi-drug resistance [31 - 35]. Cotrimoxazole and nalidixic acid were found to be 100% resistant towards 15 isolates of *Shigella boydii* and ampicillin was unable to inhibit 6 isolates of *Shigella sonnei* [31]. Multi-drug resistant species of *Salmonella* and *Shigella* were well distributed, which have attributed Shigellosis and Salmonellosis to the public health. A systematic meta-analysis of antibiotic resistance conducted for 2 decades (1993-2011) showed that two species of *Salmonella* (*Salmonella* Typhi and *Salmonella* Paratyphi A) were responsible for typhoid and paratyphoid enteric fever [36]. For both strains, *Salmonella* Typhi and *Salmonella* Paratyphi A, resistance to nalidixic acid and ciprofloxacin were sharply increased. However, for both strains, resistance to first-line antibiotics chloramphenicol and cotrimoxazole were in

decreasing trends [36]. In contrast, nalidixic acid was more resistant compared to chloramphenicol and cotrimoxazole. These results suggest that the chloramphenicol and cotrimoxazole are still useful for typhoid and paratyphoid enteric fever treatment (Table 2).

Table 2. Antibiotic resistance in *Salmonella* spp. and *Shigella* spp.

Microorganism	Study Area	No. of Isolates	Antibiotics	Resistance (%)	Reference		
<i>Shigella flexneri</i>	Nepalgunj Medical College and Teaching Hospital	29	Ampicillin	96.55	[31]		
			Nalidixic acid	96.55			
			Cotrimoxazole	72.41			
			Ciprofloxacin	62.07			
			Ceftazidime	44.83			
			Ofloxacin	37.93			
			Ceftriaxone	34.48			
<i>Shigella dysenteriae</i>		19	Nalidixic acid	94.74			
			Cotrimoxazole	84.21			
			Ampicillin	73.68			
			Ciprofloxacin	68.42			
			Gentamicin	36.84			
			Ofloxacin	21.05			
<i>Shigella boydii</i>		15	Cotrimoxazole	100			
			Nalidixic acid	100			
			Ampicillin	73.33			
			Gentamicin	33.33			
			Cefotaxime	26.67			
<i>Shigella sonnei</i>		6	Ampicillin	100			
			Nalidixic acid	83.33			
			Cotrimoxazole	83.33			
			Ciprofloxacin	33.33			
<i>Shigella</i> spp.		National Public Health laboratory, Kathmandu	21	Ampicillin		71.42	[32]
				Cotrimoxazole		66.66	
				Mecillinam		61.9	
				Nalidixic acid		47.62	
				Ciprofloxacin		23.8	
<i>Salmonella</i> spp.			9	Nalidixic acid		44.44	
				Ampicillin		33.33	
	Chloramphenicol			33.33			
	Cotrimoxazole			33.33			
<i>Shigella flexneri</i>	Tribhuvan University Teaching Hospital (TUTH), Kathmandu	12	Amoxicillin	83.33	[33]		
			Ampicillin	66.66			
			Tetracycline	66.66			
			Cotrimoxazole	58.33			
			Ciprofloxacin	58.33			
			Azithromycin	33.33			
			Ceftazidime	8.33			
<i>Shigella sonnei</i>		3	Nalidixic acid	100			
			Cotrimoxazole	100			
			Ciprofloxacin	100			
			Tetracycline	33.33			
<i>Salmonella Typhi</i>		Alka Hospital, Jawalakhel	56	Nalidixic acid		91.1	[34]
	Ampicillin			1.8			
<i>Salmonella Paratyphi A</i>	30		Nalidixic acid	90			
			Chloramphenicol	3.3			
			Ciprofloxacin	3.3			

(Table 2) contd....

Microorganism	Study Area	No. of Isolates	Antibiotics	Resistance (%)	Reference
<i>Salmonella</i> spp.	Kathmandu Model Hospital, Kathmandu	83	Nalidixic acid	83.1	[35]
			Ciprofloxacin	3.6	
			Ampicillin	2.4	
			Cotrimoxazole	1.2	
			Chloramphenicol	1.2	

2.2. Uropathogens

Urinary Tract Infection (UTI) is one of the most common infectious diseases caused by *E. coli*. In addition, *Klebsiella* spp., *Enterococcus* spp., *Enterobacter* spp., *Citrobacter* spp., and *Proteus* spp. are also associated with UTI. A report by Nepal's National Public Health Laboratory demonstrated that the resistance rates of *E. coli* for various antibiotics amoxicillin, cefixime, nalidixic acid, ceftazidime, ciprofloxacin, cotrimoxazole, norfloxacin, ofloxacin, and cefotaxime were above 50% and showed increased trend of antibiotic resistance in the year 2006 to 2010 [37]. Extended Spectrum Beta Lactamase (ESBL) producing *E. coli* exhibited 100% resistance to cephalosporins which revealed ineffectiveness in the treatment of UTI (Table 3). However, MDR *E. coli* and ESBL *E. coli* were susceptible (100%) to tigecycline, colistin, and amikacin reserving antimicrobial treatment [38, 39].

Table 3. Antibiotic resistance in *Escherichia coli*.

Microorganism	Study Area or Hospital	No. of Isolates	Antibiotics	Resistance (%)	Reference
<i>E. coli</i> (ESBL)*	National Kidney Center, Vanasthali, Kathmandu	18	Cefotaxime	100	[38]
			Ceftazidime	100	
			Ceftriaxone	100	
			Cefixime	94.44	
			Cefalexin	94.44	
			Nalidixic acid	94.44	
			Norfloxacin	94.44	
			Ofloxacin	88.89	
			Ciprofloxacin	88.89	
			Doxycycline	72.22	
			Cotrimoxazole	61.11	
			Nitrofurantoin	27.78	
<i>E. coli</i> (ESBL)	Manamohan Medical College and Teaching Hospital	288	Ampicillin	100	[39]
			Amoxicillin	100	
			Cefixime	100	
			Ceftazidime	100	
			Ceftriaxone	100	
			Aztreonam	100	
			Cephalexin	92	
			Ciprofloxacin	78	
			Tigecycline	0	
			Colistin	0	
<i>E. coli</i> (MDR)	Manamohan Medical College and Teaching Hospital	480	Ampicillin	100	[39]
			Amoxicillin	84.7	
			Cephalexin	81.6	
			Ciprofloxacin	80.6	
			Cefixime	65	
			Ceftazidime	64	
			Aztreonam	61	
			Levofloxacin	51	
			Cotrimoxazole	33	
			Tigecycline	0	
Colistin	0				

* ESBL, extended spectrum beta lactamase.

2.3. Pneumococcal Pathogens

Pneumococcal disease is an inflammatory condition of the lung. *Streptococcus pneumoniae*, *Klebsiella pneumoniae*, *Staphylococcus aureus*, *Haemophilus influenzae* type b (Hib), and *Pseudomonas aeruginosa* are common bacteria that are responsible for pneumonia in Nepal [26]. Common antibiotics used for pneumonia treatment in Nepal were cotrimoxazole, amoxicillin, and chloramphenicol [40]. In contrast, antimicrobial resistance to commonly used antibiotics ciprofloxacin and cotrimoxazole were highly increased from 2000 to 2008 [41]. Various studies reported that most of the antibiotics resistant strains of *Streptococcus pneumoniae* and *Klebsiella pneumoniae* were from clinical isolates of respiratory infections [42 - 46]. The antibiotics resistant for *Klebsiella* spp., *Streptococcus pneumoniae*, *Haemophilus influenzae*, and *Pseudomonas aeruginosa* are constantly increasing in recent years (Table 4) [47 - 49].

Table 4. Antimicrobial resistant in *Pseudomonas aeruginosa*, *Klebsiella* spp. *Streptococcus pneumoniae*, and *Haemophilus influenzae*.

Microorganism	Study Area	No. of Isolates	Antibiotics	Resistance (%)	Reference
<i>Pseudomonas aeruginosa</i>	Tribhuvan University Teaching Hospital (TUTH)	24	Ceftazidime	91.6	[47]
			Ciprofloxacin	95.8	
			Levofloxacin	87.5	
			Imipenem	62.5	
			Gentamycin	62.5	
			Cotrimoxazole	0	
			Tigecycline	0	
<i>Klebsiella</i> spp.		37	Cefotaxime	100	
			Cefepime	100	
			Cotrimoxazole	100	
			Ciprofloxacin	86.4	
			Gentamycin	83.7	
			Levofloxacin	72.9	
			Penicillin	3.57	
<i>Streptococcus pneumoniae</i>	Kanti Children's Hospital, Kathmandu	22	Cotrimoxazole	67.86	[48]
			Erythromycin	7.14	
			Cefotaxime	3.57	
<i>K. pneumoniae</i>	Mid and far western region, Nepal	36	Penicillin	88.89	[49]
			Ampicillin	44.44	
			Gentamycin	69.44	
			Ciprofloxacin	22.22	
			Chloramphenicol	47.22	
			Erythromycin	30.56	
			Tetracycline	52.78	
			Cotrimoxazole	52.78	
<i>S. pneumoniae</i>		30	Ampicillin	56.67	
			Cotrimoxazole	63.33	
			Penicillin	90	
			Chloramphenicol	40	
			Gentamycin	13.33	
			Erythromycin	33.33	
<i>Haemophilus influenzae</i>		68	Ceftriaxone	0	
	Ampicillin		54.41		
	Penicillin		91.18		
	Cotrimoxazole		47.06		
	Chloramphenicol		32.35		
	Gentamycin		16.18		
	Tetracycline		41.18		
Ciprofloxacin	16.18				

2.4. Bacteremic Pathogens

Bacteremia is well known as bacterial bloodstream infections. Serious bacterial infections include neonatal sepsis, meningitis, cellulitis, osteomyelitis, brain abscesses, pneumonia, and typhoid [50]. These infections are often serious and possibly resulting in death which requires prompt antibiotic treatment. Out of 120 isolates, 30.8% neonatal sepsis positive cases were observed in neonatal intensive care unit of Nepal Medical College Teaching Hospital (NMCTH), Kathmandu, Nepal. Among them, 56.8% were resulted from *Staphylococcus aureus* infection followed by *Klebsiella pneumoniae* (21.7%), *Pseudomonas aeruginosa* (13.4%) and others [51]. However, the resistance over different antibiotics was also frequent. Studies of sepsis infections in different hospitals reported the resistance of *Staphylococcus aureus*, *Klebsiella pneumoniae*, *Pseudomonas* spp., *Acinetobacter* spp., *Enterobacter* spp., *Citrobacter* spp., *E. coli*, and *Proteus mirabilis* ranged from 25 to 100% against commonly used antibiotics oxacillin, erythromycin, clindamycin, penicillin, cephalexin, cotrimoxazole, gentamicin, amikacin, ofloxacin, cefixime, cefotaxime, ceftazidime, piperacillin, imipenem, piperacillin-tazobactam, and ampicillin [51 - 57].

2.5. Tuberculosis Pathogens

Tuberculosis (TB) is an infectious disease caused by *Mycobacterium tuberculosis*. Resistance of *M. tuberculosis* to first line drugs isoniazid and rifampicin were extensively being increased [58]. The results of drug resistance survey (2011-2012) showed that the levels of drug resistance were high in Nepal, with nearly 9.3% of new patients and resistance among treatment cases were 15.4% [59]. In addition, the trends of Multi-Drug Resistant Tuberculosis (MDR-TB) were increased from 18.6% to 22.3% in the years 2010–2014 [59]. Furthermore, 61 new MDR-TB cases were registered in 2014 to 2015 [60]. These studies showed that the prevalence of resistance to the first-line tuberculosis drugs rifampicin and isoniazid against MDR-TB has been increased in Nepal.

2.6. Nosocomial Pathogens

Nosocomial infection is a major Healthcare Associated Infection (HCAI) in Nepal. HCAI and antimicrobial resistance were the principal threats to the patients of intensive care unit [61]. High prevalence of Methicillin-resistance *Staphylococcus aureus* (MRSA) and other bacteria were reported in most of the HCAI studies [62 - 69]. Currently, in Nepal, MDR *S. aureus* and MRSA is a major clinical threat to public health. One of the major consequences of reporting high rates of multi-drug resistant MRSA is exploitation of vancomycin (Table 5).

2.7. Sexually Transmitted Pathogens

Syphilis and gonorrhea are sexually transmitted infections of mucous membrane surfaces caused by *Treponema pallidum* and *Neisseria gonorrhoeae*, respectively. Studies on antibiotic resistance against sexually transmitted infections remain limited in Nepal. However, few identified studies reported high rate of resistance of *Neisseria gonorrhoeae* to antibiotics penicillin, tetracycline, and ciprofloxacin [70 - 72].

Table 5. Antibiotic resistance in *Staphylococcus aureus* and Methicillin-resistant *Staphylococcus aureus* (MRSA).

Microorganism	Study Area or Hospital	No. of Isolates	Antibiotics	Resistance (%)	Reference
<i>S. aureus</i>	Chitwan Medical College Teaching Hospital, Chitwan	306	Penicillin	94.7	[62]
			Cotrimoxazole	81.7	
			Cephalexin	68	
			Gentamicin	60.4	
			Ciprofloxacin	63.7	
			Erythromycin	32.7	
			Cefoxitin	43.1	
			Oxacillin	39.2	
			Clindamycin	27.5	
			Amikacin	10.7	
			Vancomycin	0	
Teicoplanin	0				

(Table 5) contd.....

Microorganism	Study Area or Hospital	No. of Isolates	Antibiotics	Resistance (%)	Reference
<i>S. aureus</i>	Universal College of Medical Sciences Teaching Hospital, Bhairahawa	162	Penicillin	81.5	[67]
			Erythromycin	71.7	
			Ampicillin	87.4	
			Amoxicillin	91.9	
			Tetracycline	39.6	
			Ciprofloxacin	26.5	
			Amikacin	19	
			Cloxacillin	69.1	
MRSA		112	Vancomycin	0	
			Penicillin	100	
			Cloxacillin	100	
			Amoxicillin	91.8	
			Ampicillin	90	
			Erythromycin	68.7	
			Cephalexin	66.03	
MRSA	Kathmandu Medical college Teaching Hospital, Kathmandu	29	Cefazolin	57.6	[69]
			Vancomycin	0	
			Penicillin	100	
			Oxacillin	100	
			Cephalexin	75.86	
			Cotrimoxazole	44.82	
			Erythromycin	44.82	
			Tetracycline	20.68	
			Gentamicin	20.68	
			Amikacin	24.13	
Ciprofloxacin	17.03				
Vancomycin	0				

2.8. Wound-Infection Pathogens

Wound-infection is one of the crucial health problem caused by the invasion of pathogenic microbes. Wound is an injury to the body by laceration or breaking of skin either from surgery, accident, war, animal bites or violence [73]. Post-operative wound-infections and injuries among children are the major health risks in Nepal [74 - 77]. Both gram positive and gram negative bacteria are associated with wound-infection. Most of the identified studies have reported *S. aureus*, *S. epidermidis*, MRSA, *E. coli*, *K. pneumoniae*, *P. aeruginosa*, *Proteus vulgaris*, *Proteus mirabilis*, *Enterococcus* spp., *Enterobacter* spp., and *Acinetobacter* spp. were associated with wound-infections [74 - 79]. Common antibiotics used for wound infections were amoxicillin (41-70% resistant), amikacin (16-80% resistant), gentamicin (19-75% resistant), cotrimoxazole (37-100% resistant), ofloxacin (23-100% resistant), ciprofloxacin (20-100% resistant), and cephalexin (40-100% resistant) [76 - 79]. The increasing multi-drug resistant wound infections are the serious issue. *S. aureus* and *E. coli* remained the most frequently isolated etiological agent for wound infection [74, 75, 78, 79]. In addition, hospital acquired wound infection; especially post operational infection has severe consequences on health and wealth burden for In-patients.

3. PREVENTIVE MEASURES

The antimicrobial resistance is a huge prime global hurdle and exponentially increasing in Nepal as well and must be addressed promptly and appropriately. Prescribing antimicrobial drugs unnecessarily, over and under dose medication of antibiotics, and unauthorized antibiotic dispensing by drug retailers are principal issues for rapid growth of antimicrobial resistance [13, 14, 16, 17]. Increasing antimicrobial resistance prolongs the illness and results failure with first-line antimicrobial drug treatment which may urge to treat with second-line or third-line drugs [14]. This is usually more expensive than first-line drugs and leads financial burden to the healthcare authorities.

Overall, antimicrobial resistance is increasing enormously. To cope with this problem discovery of new antibiotics may be choice of alternatives. But, only few novel antibiotics are being discovered in past several years. This may create a serious threat in upcoming days to the world’s public health. Furthermore, medical cost due to antimicrobial resistance is also increasing in similar pattern. Here, we recommend some strategies to reduce antimicrobial resistance

and to improve effectiveness of antibiotics in the context of Nepal based on World Health Organization (WHO) policy package to combat the spread of antimicrobial resistance on World Health Day, 2011 [80].

- Adopt the guidelines of proper antibiotic use in the hospitals and community healthcare centers.
- Improve the public health issues and find the path to reduce the need for antibiotics (Proper immunization may be a choice to reduce the use of antibiotics).
- Increase surveillance and antibiotic tracking system.
- Make strong policy for antibiotic dispensing by drug retailers.
- Ensure medical personnel to prescribe only essential drugs of assured quality (even medical personnel prescribe more than one antibiotics for a common disease).
- Regulate and promote rational use of medicines.
- Reduce the use of antimicrobial agents in agriculture and animals.
- Raise the awareness programs about antibiotic resistance and public health crisis.
- Educate the public, policy makers, and health professionals on sustainable use of antibiotics.
- Nosocomial infection should be controlled to minimize the spread of resistant bacteria.
- Prevent transmission of bacterial infections.

CONCLUDING REMARKS

Various species of gram positive and gram negative bacteria are responsible for bacterial infections to humans and animals. Majority of the bacterial isolates are resistant to commonly used antibiotics. Antimicrobial resistance is a consequential concern for Nepal as well as for all countries in the world. Over use, under use, and misuse of antibiotic is a leading cause for its resistance. The lack of proper antibiotic tracking system, AMR (antimicrobial resistance) surveillance, and facilitated laboratories are principal difficulties of Nepal. The appropriate use of antimicrobial drugs and control of spreading resistant bacteria help to maintain the effectiveness of antibiotics. A continuous monitoring and studies on the multidrug resistant bacterial isolates are important measures. In addition, national strategic approach to use antibiotics is utmost emergence to preserve effectiveness of antibiotics for future.

FUNDING INFORMATION

No fund was available for this study.

CONSENT FOR PUBLICATION

Not applicable.

CONFLICT OF INTEREST

The authors declare that there are no conflicts of interest regarding the publication of this manuscript.

ACKNOWLEDGEMENTS

Declared none.

REFERENCES

- [1] Fleming A. Penicillin. Nobel Lecture 1945.
- [2] Trujillo ME. Actinobacteria. Encyclopedia of Life Sciences (ELS). Chichester: John Wiley & Sons, Ltd 2008. [<http://dx.doi.org/10.1002/9780470015902.a0020366>]
- [3] Pimentel-Elardo SM, Kozytska S, Bugni TS, Ireland CM, Moll H, Hentschel U. Anti-parasitic compounds from *Streptomyces* sp. strains isolated from Mediterranean sponges. *Mar Drugs* 2010; 8(2): 373-80. [<http://dx.doi.org/10.3390/md8020373>] [PMID: 20390111]
- [4] Dahal RH, Shim DS, Kim J. Development of actinobacterial resources for functional cosmetics. *J Cosmet Dermatol* 2017; 16(2): 243-52. [<http://dx.doi.org/10.1111/jocd.12304>] [PMID: 28097821]
- [5] Dahal RH. Antimicrobial resistance: A major issue in global public health. *Clin Biotechnol Microbiol* 2017; 1: 186-8.
- [6] Lewis K. Platforms for antibiotic discovery. *Nat Rev Drug Discov* 2013; 12(5): 371-87. [<http://dx.doi.org/10.1038/nrd3975>] [PMID: 23629505]
- [7] Rattan A, Kalia A, Ahmad N. Multidrug-resistant *Mycobacterium tuberculosis*: Molecular perspectives. *Emerg Infect Dis* 1998; 4(2):

- 195-209.
[<http://dx.doi.org/10.3201/eid0402.980207>] [PMID: 9621190]
- [8] Gillespie SH. Evolution of drug resistance in *Mycobacterium tuberculosis*: Clinical and molecular perspective. *Antimicrob Agents Chemother* 2002; 46(2): 267-74.
[<http://dx.doi.org/10.1128/AAC.46.2.267-274.2002>] [PMID: 11796329]
- [9] Otto M. *Staphylococcus epidermidis*-the 'accidental' pathogen. *Nat Rev Microbiol* 2009; 7(8): 555-67.
[<http://dx.doi.org/10.1038/nrmicro2182>] [PMID: 19609257]
- [10] Schaefer S. *Staphylococcus epidermidis* BV: Antibiotic resistance patterns, physiological characteristics, and bacteriophage susceptibility. *Appl Microbiol* 1971; 22(4): 693-9.
[PMID: 5167101]
- [11] Eady EA, Gloor M, Leyden JJ. *Propionibacterium acnes* resistance: A worldwide problem. *Dermatology (Basel)* 2003; 206(1): 54-6.
[<http://dx.doi.org/10.1159/000067822>] [PMID: 12566805]
- [12] Boucher HW, Talbot GH, Bradley JS, *et al.* Bad bugs, no drugs: No ESCAPE! An update from the infectious diseases society of america. *Clin Infect Dis* 2009; 48(1): 1-12.
[<http://dx.doi.org/10.1086/595011>] [PMID: 19035777]
- [13] Rossolini GM, Arena F, Pecile P, Pollini S. Update on the antibiotic resistance crisis. *Curr Opin Pharmacol* 2014; 18: 56-60.
[<http://dx.doi.org/10.1016/j.coph.2014.09.006>] [PMID: 25254623]
- [14] Ventola CL. The antibiotic resistance crisis: Part 1: Causes and threats. *P&T* 2015; 40(4): 277-83.
[PMID: 25859123]
- [15] Dever LA, Dermody TS. Mechanisms of bacterial resistance to antibiotics. *Arch Intern Med* 1991; 151(5): 886-95.
[<http://dx.doi.org/10.1001/archinte.1991.00400050040010>] [PMID: 2025137]
- [16] Hamilton-Miller JM. Use and abuse of antibiotics. *Br J Clin Pharmacol* 1984; 18(4): 469-74.
[<http://dx.doi.org/10.1111/j.1365-2125.1984.tb02493.x>] [PMID: 6386026]
- [17] Wachter DA, Joshi MP, Rimal B. Antibiotic dispensing by drug retailers in Kathmandu, Nepal. *Trop Med Int Health* 1999; 4(11): 782-8.
[<http://dx.doi.org/10.1046/j.1365-3156.1999.00476.x>] [PMID: 10588773]
- [18] Centers for Disease Control and Prevention (CDC). Antibiotic resistance and threats in the United States. Atlanta 2013.
- [19] Van Boeckel TP, Gandra S, Ashok A, *et al.* Global antibiotic consumption 2000 to 2010: An analysis of national pharmaceutical sales data. *Lancet Infect Dis* 2014; 14(8): 742-50.
[[http://dx.doi.org/10.1016/S1473-3099\(14\)70780-7](http://dx.doi.org/10.1016/S1473-3099(14)70780-7)] [PMID: 25022435]
- [20] Davies J, Davies D. Origins and evolution of antibiotic resistance. *Microbiol Mol Biol Rev* 2010; 74(3): 417-33.
[<http://dx.doi.org/10.1128/MMBR.00016-10>] [PMID: 20805405]
- [21] Martinez JL, Baquero F. Mutation frequencies and antibiotic resistance. *Antimicrob Agents Chemother* 2000; 44(7): 1771-7.
[<http://dx.doi.org/10.1128/AAC.44.7.1771-1777.2000>] [PMID: 10858329]
- [22] Odonkor ST, Addo KK. Bacteria resistance to antibiotics: Recent trends and challenges. *Int J Biol Med Res* 2011; 2: 1204-10.
- [23] Department of Health Services (DoHS) Annual Report . 2015.
- [24] UN Inter-agency Group of Child Mortality Estimation (IGME). Child Mortality Estimates. 2015.
- [25] Petri WA, Miller M, Binder HJ, Levine MM, Dillingham R, Guerrant RL. Enteric infections, diarrhea, and their impact on function and development. *J Clin Invest* 2008; 118(4): 1277-90.
[<http://dx.doi.org/10.1172/JCI34005>] [PMID: 18382740]
- [26] Basnyat B, Pokharel P, Dixit S, Giri S. Antibiotic use, its resistance in Nepal and recommendations for action: A situation analysis. *J Nepal Health Res Counc* 2015; 13(30): 102-11.
[PMID: 26744193]
- [27] Thapa Shrestha U, Adhikari N, Maharjan R, *et al.* Multidrug resistant *Vibrio cholerae* O1 from clinical and environmental samples in Kathmandu city. *BMC Infect Dis* 2015; 15: 104.
[<http://dx.doi.org/10.1186/s12879-015-0844-9>] [PMID: 25888391]
- [28] Gupta PK, Pant ND, Bhandari R, Shrestha P. Cholera outbreak caused by drug resistant *Vibrio cholerae* serogroup 01 biotype EITor serotype Ogawa in Nepal; A cross-sectional study. *Antimicrob Resist Infect Control* 2016; 5: 23.
[<http://dx.doi.org/10.1186/s13756-016-0122-7>] [PMID: 27274815]
- [29] Maharjan R, Shrestha D, Acharya J, *et al.* Change in biotype trend of *Vibrio cholerae* in Nepal. *Med Micro J Microbiol* 2015; 1: 45-54.
- [30] Karki R, Bhatta DR, Malla S, *et al.* Resistotypes of *Vibrio cholerae* O1 Ogawa Biotype El Tor in Kathmandu, Nepal. *Nepal Med Coll J* 2011; 13(2): 84-7.
[PMID: 22364087]
- [31] Khan S, Singh P, Asthana A, Ansari M. Magnitude of drug resistant shigellosis in Nepalese patients. *Iran J Microbiol* 2013; 5(4): 334-8.
[PMID: 25848501]

- [32] Kansakar P, Baral P, Malla S, Ghimire GR. Antimicrobial susceptibilities of enteric bacterial pathogens isolated in Kathmandu, Nepal, during 2002-2004. *J Infect Dev Ctries* 2011; 5(3): 163-8. [http://dx.doi.org/10.3855/jidc.1016] [PMID: 21444984]
- [33] Dhital S, Sherchand JB, Pokharel BM, *et al.* Antimicrobial susceptibility pattern of *Shigella* spp. isolated from children under 5 years of age attending tertiary care hospitals, Nepal along with first finding of ESBL-production. *BMC Res Notes* 2017; 10(1): 192. [http://dx.doi.org/10.1186/s13104-017-2512-1] [PMID: 28583187]
- [34] Chand HJ, Rijal KR, Neupane B, Sharma VK, Jha B. Re-emergence of susceptibility to conventional first line drugs in *Salmonella* isolates from enteric fever patients in Nepal. *J Infect Dev Ctries* 2014; 8(11): 1483-7. [http://dx.doi.org/10.3855/jidc.4228] [PMID: 25390062]
- [35] Shrestha KL, Pant ND, Bhandari R, Khatri S, Shrestha B, Lekhak B. Re-emergence of the susceptibility of the *Salmonella* spp. isolated from blood samples to conventional first line antibiotics. *Antimicrob Resist Infect Control* 2016; 5: 22. [http://dx.doi.org/10.1186/s13756-016-0121-8] [PMID: 27231547]
- [36] Karki S, Shakya P, Cheng AC, Dumre SP, Leder K. Trends of etiology and drug resistance in enteric fever in the last two decades in Nepal: A systematic review and meta-analysis. *Clin Infect Dis* 2013; 57(10): e167-76. [http://dx.doi.org/10.1093/cid/cit563] [PMID: 23985342]
- [37] Shakya G, Upadhyay B, Rijal N, Adhikari S, Sharma S, Kansakar P. Changing trends of antibiotic resistance in *Escherichia coli*. *JHAS* 2012; 2: 42-5.
- [38] Yadav KK, Adhikari N, Khadka R, Pant AD, Shah B. Multidrug resistant *Enterobacteriaceae* and extended spectrum β -lactamase producing *Escherichia coli*: a cross-sectional study in National Kidney Center, Nepal. *Antimicrob Resist Infect Control* 2015; 4: 42. [http://dx.doi.org/10.1186/s13756-015-0085-0] [PMID: 26504518]
- [39] Parajuli NP, Maharjan P, Parajuli H, *et al.* High rates of multidrug resistance among uropathogenic *Escherichia coli* in children and analyses of ESBL producers from Nepal. *Antimicrob Resist Infect Control* 2017; 6: 9. [http://dx.doi.org/10.1186/s13756-016-0168-6] [PMID: 28096977]
- [40] Alliance for the Prudent Use of Antibiotics (APUA)-Nepal National Antibiotic Treatment Guidelines. 2014.
- [41] Shakya G. Ten-years surveillance of antimicrobial resistance pattern of *Streptococcus pneumoniae* in Nepal. *Afr J Microbiol Res* 2012; 6: 4233-8.
- [42] Easow JM, Joseph NM, Shankar PR, Rajamony AP, Dhungel BA, Shivananda PG. *Streptococcus pneumoniae* infections in western Nepal. *Southeast Asian J Trop Med Public Health* 2011; 42(4): 912-9. [PMID: 22299473]
- [43] Mishra SK, Awal BK, Kattel HP, *et al.* Drug resistant bacteria are growing menace in a university hospital in Nepal. *Am J Epidemiol Infect Dis* 2014; 2: 19-23.
- [44] Chhetri UD, Shrestha S, Pradhan R, *et al.* Clinical profile of invasive pneumococcal diseases in Patan Hospital, Nepal. *Kathmandu Univ Med J (KUMJ)* 2011; 9(33): 45-9. [KUMJ]. [PMID: 22610809]
- [45] Khanal B, Acharya A, Amatya R, *et al.* Antimicrobial resistant *Streptococcus pneumoniae*. *JNMA J Nepal Med Assoc* 2010; 49(179): 220-4. [PMID: 22049827]
- [46] Rijal B, Tandukar S, Adhikari R, *et al.* Antimicrobial susceptibility pattern and serotyping of *Streptococcus pneumoniae* isolated from Kanti Children Hospital in Nepal. *Kathmandu Univ Med J (KUMJ)* 2010; 8(30): 164-8. [KUMJ]. [PMID: 21209528]
- [47] Parajuli NP, Acharya SP, Mishra SK, Parajuli K, Rijal BP, Pokhrel BM. High burden of antimicrobial resistance among gram negative bacteria causing healthcare associated infections in a critical care unit of Nepal. *Antimicrob Resist Infect Control* 2017; 6: 67. [http://dx.doi.org/10.1186/s13756-017-0222-z] [PMID: 28638594]
- [48] Shah AS, Knoll MD, Sharma PR, *et al.* Invasive pneumococcal disease in Kanti Children's Hospital, Nepal, as observed by the South Asian Pneumococcal Alliance network. *Clin Infect Dis* 2009; 48(Suppl. 2): S123-8. [http://dx.doi.org/10.1086/596490] [PMID: 19191607]
- [49] Khan S, Priti S, Ankit S. Bacteria etiological agents causing lower respiratory tract infections and their resistance patterns. *Iran Biomed J* 2015; 19(4): 240-6. [PMID: 26220641]
- [50] Nizet V, Klein JO. Bacterial sepsis and meningitis. *Infectious Diseases of the Fetus and Newborn Infant*. 7th ed. Philadelphia, PA: Saunders 2010; pp. 222-75.
- [51] Shrestha RK, Rai SK, Khanal LK, Manda PK. Bacteriological study of neonatal sepsis and antibiotic susceptibility pattern of isolates in Kathmandu, Nepal. *Nepal Med Coll J* 2013; 15(1): 71-3. [PMID: 24592800]
- [52] Ansari S, Nepal HP, Gautam R, Shrestha S, Neopane P, Chapagain ML. Neonatal septicemia in Nepal: early-onset versus late-onset. *Int J Pediatr* 2015.
- [53] Ansari S, Nepal HP, Gautam R, *et al.* Childhood septicemia in Nepal: Documenting the bacterial etiology and its susceptibility to antibiotics.

- Int J Microbiol 2014.
- [54] Shrestha S, Adhikari N, Rai BK, Shreepaili A. Antibiotic resistance pattern of bacterial isolates in neonatal care unit. JNMA J Nepal Med Assoc 2010; 50(180): 277-81. [PMID: 22049890]
- [55] Shaw CK, Shaw P, Thapalial A. Neonatal sepsis bacterial isolates and antibiotic susceptibility patterns at a NICU in a tertiary care hospital in western Nepal: A retrospective analysis. Kathmandu Univ Med J (KUMJ) 2007; 5(2): 153-60. [PMID: 18604011]
- [56] Shrestha R, Shrestha JM, Gurung B. Antibiotic usage and its sensitivity pattern in the NICU. Kathmandu Univ Med J (KUMJ) 2012; 10(38): 27-32. [PMID: 23132471]
- [57] Gyawali N, Sanjana RK. Bacteriological profile and antibiogram of neonatal septicemia. Indian J Pediatr 2013; 80(5): 371-4. [<http://dx.doi.org/10.1007/s12098-012-0911-9>] [PMID: 23180407]
- [58] Khadka JB, Rai SK, Shrestha S, Maharjan B, Bhatta DR, Ghimire P. Study of rifampicin and isoniazid resistance mutation genes of *M. tuberculosis* isolates in Nepal. Nepal Med Coll J 2011; 13(3): 147-51. [PMID: 22808802]
- [59] Government of Nepal, Ministry of Health and Population, Department of Health Services, national Tuberculosis Center. National Tuberculosis Programme. Annual Report 2013/14; 2070(71): 2014.
- [60] Government of Nepal, Ministry of Health and Population, Department of Health Services, national Tuberculosis Center. National Tuberculosis Programme. Annual Report 2014/15; 2071(72): 2016.
- [61] Parajuli NP, Acharya SP, Mishra SK, Parajuli K, Rijal BP, Pokhrel BM. High burden of antimicrobial resistance among gram negative bacteria causing healthcare associated infections in a critical care unit of Nepal. Antimicrob Resist Infect Control 2017; 6: 67. [<http://dx.doi.org/10.1186/s13756-017-0222-z>] [PMID: 28638594]
- [62] Ansari S, Nepal HP, Gautam R, *et al*. Threat of drug resistant *Staphylococcus aureus* to health in Nepal. BMC Infect Dis 2014; 14: 157. [<http://dx.doi.org/10.1186/1471-2334-14-157>] [PMID: 24655316]
- [63] Raut S, Bajracharya K, Adhikari J, Pant SS, Adhikari B. Prevalence of methicillin resistant *Staphylococcus aureus* in Lumbini Medical College and Teaching Hospital, Palpa, Western Nepal. BMC Res Notes 2017; 10(1): 187. [<http://dx.doi.org/10.1186/s13104-017-2515-y>] [PMID: 28577365]
- [64] Kumari N, Mohapatra TM, Singh YI. Prevalence of methicillin resistance *Staphylococcus aureus* (MRSA) in a tertiary-care hospital in eastern Nepal. JNMA J Nepal Med Assoc 2008; 47(170): 53-6. [PMID: 18709031]
- [65] Sanjana R, Shah R, Chaudhary N, Shingh Y. Prevalence and antimicrobial susceptibility pattern of methicillin-resistant *Staphylococcus aureus* (MRSA) in CMS-teaching hospital: a preliminary report. J Coll Med Sci 2010; 6: 1-6.
- [66] Shrestha B, Pokhrel BM, Mohapatra TM. Antibiotic susceptibility pattern of nosocomial isolates of *staphylococcus aureus* in a tertiary care hospital, Nepal. JNMA J Nepal Med Assoc 2009; 48(175): 234-8. [PMID: 20795464]
- [67] Tiwari HK, Das AK, Sapkota D, Sivrajan K, Pahwa VK. Methicillin resistant *Staphylococcus aureus*: prevalence and antibiogram in a tertiary care hospital in western Nepal. J Infect Dev Ctries 2009; 3(9): 681-4. [<http://dx.doi.org/10.3855/jidc.86>] [PMID: 19858569]
- [68] Shakya B, Shrestha S, Mitra T. Nasal carriage rate of methicillin resistant *Staphylococcus aureus* among at National Medical College Teaching Hospital, Birgunj, Nepal. Nepal Med Coll J 2010; 12(1): 26-9. [PMID: 20677605]
- [69] Pandey S, Raza MS, Bhatta CP. Prevalence and antibiotic sensitivity pattern of methicillin-resistant *Staphylococcus aureus* in Kathmandu Medical College Teaching Hospital. J Inst Med 2012; 34: 13-7.
- [70] Bhargava D, Shakya B, Mondal K, Rijal B. Emergence of penicillin resistant *Neisseria gonorrhoeae*. J Inst Med 2010; 32: 15-8. [<http://dx.doi.org/10.3126/jiom.v32i1.3996>]
- [71] Ray K, Bala M, Kumari S, Narain JP. Antimicrobial resistance of *Neisseria gonorrhoeae* in selected World Health Organization Southeast Asia Region countries: An overview. Sex Transm Dis 2005; 32(3): 178-84. [<http://dx.doi.org/10.1097/01.olq.0000154490.40381.15>] [PMID: 15729156]
- [72] Bhatta D, Gokhale S, Ansari M, Tiwari H, Gaur A, Mathuria J. Gonococcal infections: the trends of antimicrobial susceptibility of *Neisseria gonorrhoeae* in Western Nepal. Nepal J Med Sci 2012; 1: 74-8.
- [73] Kumar RVK, Devireddy SK, Gali RS, Chaithanyaa N, Sridhar . Sridhar. A clinician's role in the management of soft tissue injuries of the face: A clinical paper. J Maxillofac Oral Surg 2013; 12(1): 21-9. [<http://dx.doi.org/10.1007/s12663-012-0352-z>] [PMID: 24431809]
- [74] Rai S, Yadav UN, Pant ND, *et al*. Bacteriological profile and antimicrobial susceptibility patterns of bacteria isolated from pus/wound swab samples from children attending a tertiary care hospital in Kathmandu. Nepal: Int J Microbiol 2017.
- [75] Pokhrel P, Shrestha A, Panthi P, Manandhar S, Chaudhary DK. Bacteriological profile and antibiotic susceptibility pattern of wound infection

- in children. *EC Microbiol* 2017; 5: 93-100.
- [76] Raza MS, Chander A, Ranabhat A. Antimicrobial susceptibility patterns of the bacterial isolates in post-operative wound infection in a tertiary care hospital, Kathmandu, Nepal. *Open J Med Microbiol* 2013; 3: 159-63. [<http://dx.doi.org/10.4236/ojmm.2013.33024>]
- [77] Shrestha S, Wenju P, Shrestha R, Karmacharya RM. Incidence and risk factors of surgical site infections in Kathmandu University Hospital, Kavre, Nepal. *Kathmandu Univ med J (KUMJ)* 2016; 14: 107-11.
- [78] Shrestha A, Sharma, VK. Bacteriological study of wound infection and antibiotic susceptibility pattern of the isolates. *Nepal J Sci Tech* 2013; 14: 143-50.
- [79] Gautam R, Acharya A, Nepal HP, Shrestha S. Antibiotic susceptibility pattern of bacterial isolates from wound infection in Chitwan Medical College Teaching Hospital, Chitwan, Nepal. *Int J Biol Adv Res* 2013; 4: 248-52. [<http://dx.doi.org/10.7439/ijbar.v4i4.302>]
- [80] WHO. Policy package to combat antimicrobial resistance. World Health Day 2011: policy briefs 2011.

© 2018 Dahal and Chaudhary.

This is an open access article distributed under the terms of the Creative Commons Attribution 4.0 International Public License (CC-BY 4.0), a copy of which is available at: (<https://creativecommons.org/licenses/by/4.0/legalcode>). This license permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.